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Abstract 
The pharmacological therapy for inflammatory bowel diseases is still a challenge. 
Current treatment still requires new alternative options. In this study, we tested the 
hypothesis that carvacrol (CAR), a phenolic monoterpene with anti-inflammatory and 
antioxidant activities, can treat experimental colitis in mice. C57BL/6 mice (n=8/group) 
were submitted to intrarectal administration of acetic acid (5%) to induce colitis. Mice 
were pretreated with CAR (25, 50 or 100 mg/kg, p.o.) during three days (every 12 
hours) before the induction. Abdominal hyperalgesia, macroscopic and microscopic 
colon damage, myeloperoxidase (MPO) activity, tumoral necrosis factor (TNF)-α and 
interleukin (IL)-1β levels, oxidative stress markers and antioxidant enzyme activities 
were evaluated. Pretreatment with all doses of CAR significantly decreased abdominal 
hyperalgesia and colon MPO activity and TNF-α and IL-1β levels. A reduction of 
macroscopic and microscopic damage (p<0.05) was observed for the doses of 50 and 
100 mg/kg of CAR. Pretreatment with CAR significantly reduced lipid peroxidation 
(for all doses) and increased sulfhydryl groups (for 100 mg/kg). This effect was 
accompanied by a significant increase of catalase, superoxide dismutase and glutathione 
peroxidase activities. These findings indicate that CAR protected mice from acetic acid-
induced colitis by reduction of inflammatory, nociceptive and oxidative damages. 
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1. Introduction 
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes 
disrupted homeostasis and uncontrolled intestinal inflammation [1, 2]. Unlike Crohn’s 
disease, UC is restricted to the colon and rectum [3]. The main symptoms of UC include 
diarrhea, abdominal cramps and recurrent blood in the stool caused by mucosal ulcers 
[4]. Although the etiology of UC is still not completely established, it is known that 
multiple factors are associated with its pathogenesis, such as genetic susceptibility, 
environmental and microbial factors [5] and the imbalance between immune system and 
intestinal microbes [6, 7]. Several studies have provided evidence that tumoral necrosis 
factor (TNF)-α is a key cytokine in the onset of UC, suggesting that the presence of the 
308 G/A allele could confer a relative risk of 3.62 to develop UC in the general 
population [8]. 
Epidemiologic data have shown increasing global incidence and prevalence of UC 
in recent decades. In a military population-based study in the USA, Porter, et al. [9] 
found prevalence of 21.9/100 000 cases of UC per year, which in turn appeared to have 
a positive correlation with the elevated number of life stressors. Recently, Santos, et al. 
[10] showed that up to 20% of patients with UC needed to undergo colectomy due to 
complications of the disease in Brazil. 
The current pharmacological therapy for patients with UC includes non-selective 
anti-inflammatory drugs and corticosteroids\immunosuppressants [11], as well as anti-
TNF-α agents [12]. These drugs are used to maintain long-term remission, reduction of 
abnormal colonic inflammation and control of clinical symptoms, such as diarrhea, 
rectal bleeding and abdominal pain. However, the continuous use of these medications 
can cause serious side effects to patients (e.g., gastric ulcer formation, hyperglycemia, 
glaucoma and muscle weakness [13] and increased rates of infections, malignancies and 
other adverse events [14]). Thus, a great effort has been made to develop new drugs to 
treat UC.  
Reports from the literature indicate that the use of medicinal plants is an alternative 
approach to the treatment of experimental UC [15]. Medicinal plants are sources of 
diverse pharmacologically active compounds, like monoterpenes, which can be obtained 
from a number of aromatic plants, including those from the genera Lippia and 
Origanum [16]. Carvacrol (5-isopropyl-2-methylphenol) is a phenol monoterpene that 
possesses a variety of pharmacological properties, including antioxidant, antibacterial, 
hepatoprotective, anti-inflammatory, antinociceptive and gastroprotective activities, 
among others [17-20]. In this study, we evaluated the effects of carvacrol against acid 
acetic-induced colitis in mice. 
 
2. Material and methods 
2.1. Reagents 
5-Aminosalicylic acid, 2,4-dinitrochlorobenzene, adrenaline, aprotinin A, Bradford 
reagent, benzomethonium chloride, bovine serum albumin, catalase, cremophor, 
carvacrol, dinitricbenzoic acid, glutathione reductase, glutathione, 
hexadecyltrimethylammonium bromide (HTAB), o-dianisidine hydrochloride, 
ethylenediaminetetraacetic acid (EDTA), tert-butyl hydroperoxide, horseradish 
peroxidase, nicotinamide adenine dinucleotide phosphate reductase (NADPH), and 
phenylmethylsulfonyl fluoride propionyl chloride were purchased from Sigma (St. 
Louis, MO, USA). Enzyme-linked immunosorbent assay (ELISA) for mouse 
quantitative determination of TNF-α and IL-1β was obtained from R&D Systems 
(Minneapolis, MN, USA). Isoflurane was obtained from Cristália (Itapira, SP, Brazil). 
Acetic acid and sulfuric acid were obtained from Êxodo Científica (Hortolândia, SP, 
Brazil). All other reagents were obtained from Merck (São Paulo, SP, Brazil). 
2.2. Animals 
Male C57BL/6 mice (25-30 g) were obtained from the Animal Center of Federal 
University of Sergipe. They were randomly housed in appropriate cages at 22±2 °C on a 
12-hour light/dark cycle (lights on from 6:00 a.m. to 6:00 p.m.), with free access to food 
(Purina, Brazil) and tap water. The animals were randomly distributed among the 
experimental groups. All experimental and euthanasia procedures were performed 
according to the National Laboratory Health and Use Guide (NIH) and International 
Council for Laboratory Animal Science (ICLAS), and were approved by the Research 
Ethics Committee of Federal University of Sergipe under no. 15/2014. The visual 
observers that carried out the nociceptive test and macroscopic and microscopic analysis 
were blinded from identification of the experimental groups. 
2.3. Experimental design and colitis induction 
Animals were divided into six groups (n = 8). Mice in group I (Vehicle + Saline) 
were pretreated with cremophor (0.05% prepared in 0.9% saline, as the vehicle for 
CAR) every 12 hours, per oral (p.o.), at 0.1 mL/10 g of body weight, during three days. 
In group II (Vehicle + Colitis), mice were also pretreated with cremophor in the same 
way. Groups III, IV and V (CAR + Colitis) were submitted to pretreatment with CAR at 
25, 50 and 100 mg/kg 
26,27
 respectively (every 12 hours, p.o., 0.1 mL/10 g, during three 
days and group VI (5-ASA + Colitis) received pretreatment with 5-ASA (100 mg/kg, 
every 24 hours, during three days [21].  
On the third day, one hour after the last pretreatment, animals from groups II to 
VI were submitted to colitis induction according to previous studies [22, 23], with 
minor modifications. Briefly, mice were submitted to isoflurane (1-2%) anesthesia and a 
colon lavage was performed with 2 mL of 0.9% saline solution, with the aid of a 
flexible catheter (3.5 F) with approximately 3 cm in the proximal portion of the anus. 
Then 150 µL of 5% acetic acid solution (v/v) prepared in saline was transrectally 
instilled into the lumen of the colon. After administration of acetic acid, mice were 
maintained in a supine position for 30 s to prevent leakage of the intracolonically 
instilled solution. Animals from group I were submitted to the same procedure using an 
equal volume of saline instead of acetic acid solution. Twenty-four hours later the 
animals were euthanized by excess of inhaled isoflurane (5%) and colon tissue was 
collected for analysis. 
2.4. Evaluation of colon macroscopic damage 
After euthanasia, colons were immediately removed and washed in 10 mmol/L 
phosphate buffered saline (PBS) solution (pH 7.4). The severity of colonic lesion was 
evaluated using a macroscopic scale that considered the scores 0 (no macroscopic 
changes), 1 (only mucosal erythema), 2 (mild mucosal edema, slight hemorrhage or 
minor erosion), 3 (mild edema, mild ulcers, bleeding or erosions) and 4 (severe 
ulceration, edema and tissue necrosis), according to previous studies[22, 24]. 
2.5. Evaluation of inflammatory biomarkers 
The myeloperoxidase (MPO) activity was measured using the technique 
described by Bradley, et al. [25]   with minor modifications. Colon samples (~ 100 mg) 
were collected, weighed, cut into small pieces and homogenized in potassium phosphate 
buffer (50 mmol/L, pH 6.0, containing 0.5% HTAB). Then 1-mL aliquots of the 
homogenate were centrifuged (10 min, 18,000 g, 4 °C) to obtain the supernatant. In a 
96-well plate, 20 μL of the supernatant was pipetted and 200 μL of a solution containing 
o-dianisidine dihydrochloride (0.167 mg/mL, prepared in 50 mmol/L of potassium 
phosphate buffer containing 0.005% of H2O2). The results were expressed as units of 
MPO per mg of tissue (UMPO/mg tissue). 
The levels of TNF-α and IL-1β were quantified in colon tissues through enzyme 
immunoassay (ELISA) according to the manufacturer’s instructions. For this 
determination, colons were removed and homogenized in PBS (in mmol/L NaCl 137; 
KCl 2.7; Na2HPO4 8.1; KH2PO4 1.5, pH 7.2) containing Tween 20 (0.05%), PMSF 
(0.1 mmol/L), benzomethonium chloride (0.1 mmol/L), EDTA (10 mmol/L) and 
aprotinin A (2 ng/mL). The amount of protein in each sample was measured using the 
Bradford method and the results were expressed in pg of cytokine/mg of protein. 
2.6. Histological analysis 
For the histological evaluation, colons were removed and fixed with 10% 
buffered formalin. These samples were embedded in paraffin, following routine 
histological processing, and cut into 5 µm sections and stained with hematoxylin and 
eosin. The presence of architecture loss, cellular infiltrate mucosa, muscle submucosa 
thickening, abscess formation in crypts/hemorrhage and depletion of goblet cells was 
assessed by a qualitative score that considered: 0 (no detectable changes), 1 (mild 
injury), 2 (moderate injury), and 3 (severe injury) [26]. Qualitative analysis was 
performed on 400× magnified images. 
2.7. Measurement of abdominal hyperalgesia 
The mechanical abdominal hyperalgesia was evaluated with the electronic von 
Frey test[27]. Animals were acclimated for 30 minutes before the test in individual 
cages and mechanical stimuli were applied in the abdomen of each animal. The first 
measurement was performed before colitis induction by acetic acid (basal) and the 
second measurement was performed 23 hours after induction.  
For each measurement, the electronic von Frey tip was applied as a stimulus of 
increasing pressure in the lower abdominal region until the mice presented a withdrawal 
response. The force required to cause this response was considered the threshold value. 
This procedure was performed in triplicate and the mean was used for each animal. The 
test was performed in a covert manner, so that the examiner who carried out the 
measurements had no knowledge about the experimental groups.  
The variation () of stimulus intensity (expressed in grams) was calculated by 
subtracting the values obtained after induction from the basal values. 
2.8. Evaluation of oxidative stress and antioxidant enzyme activity 
Samples of colon were homogenized in potassium phosphate buffer (50 mmol/L, 
pH 7.4, 1 g of tissue/5 mL of buffer). The amount of protein in each sample was 
measured using the Bradford method.  
The determination of the thiobarbituric acid reaction products was performed 
according to a previous description [28]. Briefly, the homogenate (100 μL) was added 
with 950 μL of the acid solution (20% acetic acid and 0.5% thiobarbituric acid), agitated 
and incubated at 85 °C for 60 min. After incubation, samples were centrifuged for 5 min 
at 18,000 g. The supernatant absorbance was read at 535 nm in a microplate reader and 
corrected by the reading at 572 nm. The results were calculated using the molar 
extinction coefficient of 1.55×10
5
 mol
−1
.L.cm
−1
 and expressed as nmols of 
malondialdehyde (MDA) per mg of tissue.  
The sulfhydryl groups content of the proteins was measured as previously 
described [29]. Colon homogenate samples (50 µg of proteins in 50 μL) were reacted 
with 10 μL of dinitricbenzoic acid for 1 hour and the absorbance was read at 412 nm. 
Results were expressed as SH (µmol/mg of protein). 
The catalase (CAT) activity was determined as previously described [30]. The 
homogenate (300 μL) was incubated with 500 μL of H2O2 (10 mmol/L) and after 5 min 
the reaction was stopped with 500 μL of 1 mmol/L of NaN3 and 200 μL of HRP reagent 
was added. The absorbance was detected at 460 nm and the results were plotted against 
an H2O2 curve and expressed as units of CAT/mg of protein. 
The analysis of superoxide dismutase (SOD) was based on the inhibition of the 
reaction of the superoxide radical with adrenaline [31]. The SOD reaction was 
performed as a protein curve for each sample (7.5 µg, 15 µg and 30 µg of protein), 
which was incubated in the presence of catalase (5 µL, 10 µmoL/L) and then adrenaline 
(5 µL, 60 mmol/L). The kinetic reading was performed during 10 min at 480 nm at a 
temperature of 32 °C and the values were expressed as units of SOD/mg protein. 
The activity of glutathione peroxidase (GSH-Px) was determined according to 
the method described by Paglia and Valentine [32]. For this assay, 30 µL of 
homogenate was added to 5 µL of GSH (0.08 mol/L), 5 µL of GR (9.6 U/mL), 145 µL 
of phosphate buffer (50 mmol/L) and EDTA (0.1 mol/L) and incubated for 5 min at 37 
°C. Then, 5 μL of tert-butyl hydroperoxide (0.3%) and 10 μL of NADPH (1.2 mmol/L) 
were added and the assay was monitored at 340 nm for 10 min at 37 °C. The results 
were expressed as µmol of GSH/min/mg of protein. 
The determination of glutathione S-transferase (GST) was performed according 
to a previous study
 
[33]. In this assay, 10 μL of homogenate is added to 5 μL of 1-
chloro-2,4-dinitrobenzene (0.1 mol/L) following incubation for 10 min and addition of 5 
μL of GSH (0.1 mol/L). The absorbance was monitored for 15 min (25 °C, 340 nm). 
The results were expressed in μmol of GSH conjugate/min/mg of protein. 
2.9. Statistical analysis 
The results were expressed as mean ± S.E.M and data were analyzed by using 
the GraphPad Prism software (San Diego, CA, USA) version 5.0. Parametric data were 
analyzed by one-way analysis of variance (ANOVA) followed by the Tukey test. 
Nonparametric data (macroscopic and microscopic scores) were analyzed by the 
Kruskal-Wallis test followed by Dunn’s test. Differences were considered significant if 
p<0.05. 
 
3. Results and Discussion 
3.1. Pretreatment with CAR reduces colon inflammation 
Treatment with CAR (50 and 100 mg/kg), performed three days before colitis 
induction, reduced (p<0.05 for 50 mg/kg and p<0.01 for 100 mg/kg) the macroscopic 
damage (mucosal edema, ulceration, hemorrhage and/or erosions) induced by acetic 
acid (5%), when compared to animals pretreated with vehicle (Figure 1A). Although 
this effect was significantly observed from the dose of 50 mg/kg, pretreatment with all 
doses reduced MPO activity (p<0.001), as did pretreatment with the positive control 
drug, 5-ASA (100 mg/kg; p<0.01, Figure 1B). These results suggest that CAR protected 
mice from the acute injury caused by acetic acid and that inhibition of neutrophil 
infiltration is an event related to this beneficial effect. Since neutrophils are strongly 
modulated by cytokines like TNF-α and IL-1β [34], we measured the concentration of 
these mediators in the colon tissue and observed that the pretreatment with CAR 
consistently inhibited TNF-α (p<0.001 for all doses) and IL-1β levels (p<0.01 for 25 
mg/kg and p<0.001 for 50 and 100 mg/kg). A significant reduction of TNF-α, but not 
IL-1β, was also achieved by pretreatment with 5-ASA (Figures 1C and D). These results 
are in agreement with previous studies that showed that CAR (25-100 mg/kg) 
attenuated the neutrophil influx and TNF-α production during pleurisy induced by 
carrageenan in mice [35], reduced the TNF-α and IL-1β mRNA expression and 
production in mice paws injected with complex Freund adjuvant [36], and decreased the 
MPO activity and cytokine levels in irinotecan-induced intestinal mucositis [37].  
Corroborating these results, the histological analysis of colon tissues revealed 
that the alterations induced by intrarectal acetic acid administration (loss of tissue 
architecture, cellular infiltrate in the mucosa, submucosa muscle thickening, abscess 
formation and hemorrhage in crypts and depletion of goblet cells) were less observed in 
animals treated with all doses of CAR or 5-ASA (Figures 2A-F). These findings were 
confirmed by the lower total histopathological scores of colon slices from mice 
pretreated with CAR (p<0.05), when compared to the vehicle group. This effect was 
also observed for 5-ASA (p<0.05) (Figure 2G). 
3.2. Pretreatment with CAR reduces abdominal hyperalgesia  
As a consequence of colitis induction, mice developed abdominal hyperalgesia. 
This effect was measured 23 hours after colitis induction as the decreased intensity of 
mechanical stimulus needed to cause withdrawal behavior in mice injected with acetic 
acid (p<0.001, Figure 3), compared with animals injected with saline. This result agrees 
with previous descriptions of alterations in the visceral sensitivity in rats submitted to 
acetic acid-induced colitis [38]. Visceral pain was also described in the model of colitis 
induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS) in rats [39]. Besides this, 
visceral pain is one of the main complaints of patients with UC [40], reinforcing the 
translational potential of evaluating abdominal hyperalgesia in experimental colitis.  
Interestingly, the pretreatment with CAR produced an inhibitory effect (p<0.05 
for 25 and 100 mg/kg and p<0.001 for 50 mg/kg) on the mechanical abdominal 
hyperalgesia provoked by acetic acid-induced colitis, as did 5-ASA (p<0.001, Figure 3).  
Further studies have shown that CAR causes antinociceptive effects in mice.  
Guimaraes, et al. [35] showed that pretreatment of mice with CAR (25-100 mg/kg, i.p.) 
reduced acetic acid-induced abdominal writhing, decreased formalin, glutamate or 
capsaicin-induced paw licking and increased latency in the hot plate test. Another study 
also demonstrated that CAR (50 or 100 mg/kg, i.p.) decreased the mechanical 
hyperalgesia caused by carrageenan, TNF-α, prostaglandin E2 and dopamine injection in 
mice paw [41]. Treatment with CAR (50 mg/kg, s.c.) also reduced mechanical 
hyperalgesia and spontaneous or palpation-induced nociception in mice with cancer 
pain. This effect was associated with reduced cFos positive neurons in lamina I of spinal 
cord and increased cFos positive neurons in descending inhibitory pain pathway 
structures, confirming the modulation of central nociceptive mechanisms by CAR [41]. 
Altogether, these studies have suggested the possibility that the anti-hyperalgesic 
effect of CAR observed in our study might be a consequence of decreased colon 
inflammation or modulation of the central nervous system.  
A mechanistic possibility for CAR actions is the activation of the transient 
receptor potential A1 (TRPA1) [42]. Intriguingly, this receptor is involved in the 
mechanical hypersensitivity of the colon through direct activation of sensory fibers, 
leading to the production of substance P and calcitonin gene-related peptide Bautista, et 
al. [43]. The exact role of TRPA1 receptors in colitis is still controversial, since 
substance P is essential for the development of colitis by TNBS or dextran sulphate 
sodium [44], but CGRP protected mice from colon damage by TNBS [45]. 
Nevertheless, a previous study demonstrated that cannabichromene, a TRPA1 agonist, 
reduced colitis induced by dinitrobenzene sulphonic acid in mice [46]. Of interest, 
capsazepine, a well-known TRPV1 antagonist, was recently described as an activator of 
TRPA1 and the topical administration (enema) of capsazepine to mouse colons initially 
led to a nociceptive response, but this response was susceptible to desensitization after 4 
days of administration [47]. This study supports the possibility that the reversion of 
hyperalgesia by CAR in the model of acetic acid-induced colitis could account for the 
desensitization of the TRPA1 receptor.  
3.3. Modulation of oxidative stress and antioxidant enzymes by CAR  
It is well known that CAR possesses antioxidant activity in vitro [48] and in vivo 
[49-51]. The possibility that the oxidative stress plays a role in the effect of CAR was 
investigated through measurement of oxidative stress markers and antioxidant enzyme 
activity during colitis induced by acetic acid. Figure 4A demonstrates that the lipid 
peroxidation observed in inflamed colon was lower in mice treated with CAR (p<0.01 
for 25 mg/kg and p<0.001 for 50 and 100 mg/kg) or 5-ASA (p<0.001) when compared 
to the vehicle + colitis group. Also, colon inflammation by acetic acid decreased the 
sulfhydryl groups content in colon (p<0.001) and the pretreatment with CAR and 5-
ASA, at a dose 100 mg/kg, reversed this oxidative effect (p<0.05) when compared to 
the vehicle + colitis group (Figure 4B). 
Since these antioxidant effects observed of CAR in the colonic tissue could 
occur due to modulation of antioxidant enzymes, the activities of CAT, SOD, GPx and 
GST were evaluated. Figure 5(A-D) shows that the induction of colitis decreased the 
activities of these enzymes (p<0.001) when compared to the vehicle + saline group. 
Pretreatment with CAR partially reverted the deleterious effect of acetic acid on the 
activity of CAT (p<0.05 for 25 and 100 mg/kg), SOD (p<0.01 for 100 mg/kg) and GPx 
(p<0.05 for all doses), without affecting the activity of GST, in comparison to the 
vehicle plus colitis group (Figure 5). The administration of 5-ASA also restored the 
activity of CAT (p<0.001), SOD (p<0.001), GPx (p<0.001) and GST (p<0.05), when 
compared with the vehicle + colitis group (Figure 5).  
These results suggest that the mechanisms underlying the protective effects of 
CAR on acetic acid-induced colitis can account for the reduction of oxidative stress in 
the mouse colon. Although this association is reasonable, it should be considered that 
the decrease in oxidative stress could be caused by the lower inflammatory damage to 
the colon. In any event, a striking feature of colitis induced by acetic acid or other 
agents is the presence of oxidative damage, which plays a critical role in the initiation 
and progression of colitis [52-54]. Thus, excessive reactive species causes colon 
damage and contributes to the formation of secondary messengers that activate 
intracellular signaling pathways and exacerbate inflammation, leading to widespread 
effects [55]. Corroborating our findings, previous studies have reported the antioxidant 
effect of CAR in the models of colitis-associated colon cancer in rats [49], irinotecan-
induced intestinal mucositis in mice [37], liver damage in elderly rats [50] and 
doxorubicin-induced cardiotoxicity in rats [51]. 
In summary, CAR attenuated acetic acid-induced colitis in mice through anti-
inflammatory mechanisms by inhibiting TNF-α and IL-1β and reducing oxidative 
damage with the participation of antioxidant enzymes, which collectively led to 
reduction of abdominal hyperalgesia. These results demonstrate the potential of CAR 
for the treatment of colitis.  
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Figure legends: 
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Figure 1. Pretreatment with carvacrol (CAR: 25, 50, or 100 mg/kg) reduces colon 
inflammation induced by acetic acid. Animals (n=8) were pretreated with CAR (p.o.) 
or 5-aminosalicylic acid (5-ASA; 100 mg/kg, p.o.) and colitis was induced by 
intracolonic injection of acetic acid (5%). Panel A shows the box-and-whisker plots 
(minimum to maximum) for the macroscopic score for colonic damage. Panels B, C and 
D demonstrate the mean±SEM for the units of myeloperoxidase activity (UMPO)/mg of 
colonic and the levels of tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-
1β), respectively. ###p<0.001 vs. vehicle + saline group; **p<0.01 or ***p<0.001 vs. 
vehicle + acetic acid group (Panel A: Kruskal-Wallis followed by Dunn’s test; panels B, 
C and D: one-way ANOVA followed by Tukey test). 
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Figure 2. Pretreatment with carvacrol reduces histological alterations induced by 
acetic acid 5% in mice colon. Images were captured at 10-fold magnification of colon 
tissue slices stained with hematoxylin and eosin. Normal structure of colon tissue is 
demonstrated in the vehicle + saline group (Panel A). Panel B shows the loss of 
integrity of colon architecture in animals from vehicle + acetic acid group. Panels C, D 
and E represent the tissues of animals pretreated with carvacrol (25, 50 and 100 mg/kg, 
respectively) and Panel F represents the tissue of mice pretreated with 5-ASA (100 
mg/kg). The sum of histopathological scores is represented in Panel G as a box-and 
whisker plot (minimum to maximum). 
##
p<0.01 vs. vehicle + saline group; 
*
p<0.05 vs. 
vehicle + acetic acid group (Kruskal-Wallis followed by Dunn’s test, n=4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Pretreatment with carvacrol (CAR: 25, 50, or 100 mg/kg) decreases 
abdominal hyperalgesia in mice submitted to acetic acid-induced colitis. Animals 
(n=8) were pretreated with CAR (p.o.) or 5-aminosalicylic acid (5-ASA; 100 mg/kg, 
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p.o.) and colitis was induced by intracolonic injection of acetic acid (5%). Data are 
shown as mean±SEM (n=8) of the variation () of the withdrawal threshold (in grams) 
to tactile stimulation of the abdomen before and after xx hours of induction of colitis. 
###
p<0.001 vs saline group; 
*
p<0.05 or 
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p<0.001 vs. vehicle + acetic acid group (one-
way ANOVA followed by Tukey test). 
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Figure 4. Pretreatment with carvacrol (CAR) reduces oxidative stress in colon 
tissue. Animals (n=8) were pretreated with CAR (p.o.) or 5-aminosalicylic acid (5-
ASA; 100 mg/kg, p.o.) and colitis was induced by intracolonic injection of acetic acid 
(5%). Lipoperoxidation, measured as the concentration of malondialdehyde (MDA; 
Panel A) and sulfhydryl groups (SH; panel B) were determined in colon tissue. Data are 
expressed as mean±SEM for n=8. 
###
p<0.001 vs. vehicle+saline group and 
*
p<0.05; 
**
p<0.01 or 
***
p<0.001 vs. vehicle+acetic acid group (one-way ANOVA followed by 
Tukey test). 
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Figure 5. Modulation of antioxidant enzymes activity by pretreatment with 
carvacrol. Animals (n=8) were pretreated with CAR (p.o.) or 5-aminosalicylic acid (5-
ASA; 100 mg/kg, p.o.) and colitis was induced by intracolonic injection of acetic acid 
(5%). Catalase (CAT, Panel A), superoxide dismutase (SOD, Panel B), glutathione 
(GSH) peroxidase (Panel C) and GSH transferase (Panel D) activities were measured in 
colon tissue of mice. Data are expressed as mean±SEM for n=8. 
##
p<0.01 or 
###
p<0.001 
vs. vehicle+saline group and 
*
p<0.05; 
**
p<0.01 or 
***
p<0.001 vs. vehicle+acetic acid 
group (one-way ANOVA followed by Tukey test). 
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